These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A multicentre randomized double-blind study comparing two dosages of levamisole in rheumatoid arthritis.
    Journal: J Rheumatol Suppl; 1978; 4():5-10. PubMed ID: 366143.
    Abstract:
    A six-centre study was conducted to evaluate the effectiveness and safety of a single weekly treatment with 50 or 150 mg levamisole in patients with rheumatoid arthritis (RA). The results were compared with those of a previous placebo-controlled study, in which 150 mg levamisole was given on 3 or 7 consecutive days each week. The efficacy/side effect ratio is better with 150 mg once weekly than with 150 mg on 3 or 7 consecutive days each week. A reduction of the dose to 50 mg reduces the incidence of idiosyncratic reactions but also reduces efficacy. A single dose of 150 mg levamisole once weekly is therefore recommended as a standard dose in patients with RA. This regimen allows for hematological controls at critical times and, hence, permits recognition in practice of agranulocytosis at the incipient stage.
    [Abstract] [Full Text] [Related] [New Search]